Keryx shares spike as cancer drug wins fast track

With a late-stage trial for the colorectal cancer drug KRX-0401 looming this quarter, Aeterna Zentaris and partner Keryx say they won fast-track status from the FDA for the program. Keryx shares jumped 22 percent on the news. Keryx release | Report